vxa-cov2-1.1-s
·Code: VXA-CoV2-1.1-S
vxa-cov2-1.1-s: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Vaxart, Inc. (VXRT) | Phase 2 |
Clinical Trials (1)
A Phase 2, Double-Blind, Multi-Center, Randomized, Placebo-Controlled, Dose-Ranging Trial to Determine the Safety, Immunogenicity and Efficacy of an Adenoviral-Vector Based Vaccine Expressing Severe Acute Respiratory Syndrome (SARS-CoV-2) and dsRNA Adjuvant Administered Orally
Frequently asked questions
Who is developing vxa-cov2-1.1-s?
vxa-cov2-1.1-s is being developed by Vaxart, Inc..
How many clinical trials involve vxa-cov2-1.1-s?
BioSniper tracks 1 clinical trial involving vxa-cov2-1.1-s.
Get deeper analysis on vxa-cov2-1.1-s
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis